Notice: Function WP_Scripts::add was called incorrectly. The script with the handle "jquery" was enqueued with dependencies that are not registered: jquery-migrate. Please see Debugging in WordPress for more information. (This message was added in version 6.9.1.) in /var/www/vhosts/hemostasistoday.com/public_html/wp-includes/functions.php on line 6131

Hemostasis Today

February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Abhishek Paserkar։ Revolutionizing Hypertriglyceridemia Treatment With Olezarsen
Feb 3, 2026, 16:05

Abhishek Paserkar։ Revolutionizing Hypertriglyceridemia Treatment With Olezarsen

Abhishek Paserkar, Medical Doctor, shared a post on LinkedIn:

՛՛Revolutionizing Hypertriglyceridemia Treatment!

Excited to dive into this groundbreaking review on Olezarsen (Tryngolza) – the next-gen GalNAc-conjugated antisense oligonucleotide targeting ApoC-III for severe hypertriglyceridemia and Familial Chylomicronemia Syndrome (FCS)!

Published in Cureus (Nov 2025) by Joshy et al., it highlights how olezarsen slashes triglycerides by ~60% in FCS patients over 12 months, dramatically cutting pancreatitis events (just 1 vs. 11 on placebo in BALANCE trial)!

Key Highlights
Mechanism Magic: Inhibits hepatic ApoC-III, boosting LPL-dependent and independent triglyceride clearance – even in LPL-deficient FCS!

Trial Triumphs: Phase 3 BALANCE: TG decreased 59%, ESSENCE: decreased 58-61% in moderate HTG + CV risk. Ongoing CORE trials target pancreatitis prevention in severe HTG.

Safety Superstar: Mild injection-site reactions only; no thrombocytopenia like older volanesorsen. Monthly 80mg SC dose – convenient and tolerable!

This precision therapy (FDA-approved Dec 2024) transforms management of life-threatening TG disorders, paving the way for CV risk reduction. A must-read for pharmacologists, endocrinologists and lipid experts! ՛՛

Abhishek Paserkar։ Revolutionizing Hypertriglyceridemia Treatment With Olezarsen

Stay updated with Hemostasis Today.